Bupropion/zonisamide

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Bupropion/zonisamide
Combination of
Bupropion Norepinephrine reuptake inhibitor/releasing agent and nicotinic acetylcholine receptor antagonist
Zonisamide Sulfonamide anticonvulsant
Clinical data
  • Investigational
Identifiers
 YesY (what is this?)  (verify)

Bupropion/zonisamide (planned trade name Empatic) is an experimental drug combination for the treatment of obesity.[1] It is being developed by Orexigen Therapeutics. It is currently at phase II testing.[2][3] The combination consists of two prescription medications approved by the U.S. Food and Drug Administration (FDA) for other ailments.[4] When mixed together and tested along with proper diet and moderate exercise, they produced a substantial weight loss effect higher than the group taking a placebo.

Empatic was called Excalia before its name was changed.[5]

See also[edit]

References[edit]

  1. ^ Empatic Shows Long-Term Weight Loss, Improved Quality Of Life Contrave(R) Reduces Rate Of Metabolic Syndrome By Half
  2. ^ Ioannides-Demos, LL; Piccenna, L; McNeil, JJ (2011). "Pharmacotherapies for obesity: past, current, and future therapies." (PDF). Journal of Obesity 2011: 179674. doi:10.1155/2011/179674. PMC 3006492. PMID 21197148. 
  3. ^ Adan, RAH (February 2013). "Mechanisms underlying current and future anti-obesity drugs". Trends in Neurosciences 36 (2): 133–140. doi:10.1016/j.tins.2012.12.001. PMID 23312373. 
  4. ^ Orexigen says trial of 2nd obesity drug meets goal
  5. ^ Empatic Obesity Drug Information and News